The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Psoriasis and Pustular Dermatitis Triggered by TNF-α Inhibitors in Patients With Rheumatologic Conditions
Abstract
BACKGROUND: New onset or worsening of psoriasis has been reported in patients treated with tumor necrosis factor alpha (TNF-alpha) inhibitors for a variety of rheumatologic conditions. There is mounting evidence that a key innate immune pathway for triggering common human autoimmune disease, including psoriasis, involves plasmacytoid dendritic cell precursors (PDCs) and type 1 interferon (IFN) production. We present herein a case series with clinical and histopathologic evidence of psoriasis in patients with rheumatologic disease treated with TNF-alpha inhibitors. We propose that the cross regulation between TNF-alpha and IFN may have a role in the pathogenesis of this reaction. OBSERVATIONS: We observed new-onset psoriasis (n = 13) or severe exacerbation of psoriasis (n = 2) in 15 patients with a variety of rheumatologic conditions-rheumatoid arthritis (n = 13), psoriatic arthritis (n = 1), and seronegative arthritis (n = 1)-during treatment with etanercept (n = 6), infliximab (n = 5), and adalimumab (n = 4). Immunohistochemical staining of skin biopsy specimens for myxovirus-resistance protein A (MxA, a surrogate marker for lesional type 1 IFN activity) showed increased staining in TNF-alpha inhibitor-induced psoriasis compared with psoriasis vulgaris. CONCLUSIONS: New onset or severe exacerbation of psoriasis is a rare complication of TNF-alpha inhibitor therapy. The finding of increased production of IFN-alpha in TNF-alpha inhibitor-induced psoriasis is a possible pathophysiologic explanation for this reaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Plasmacytoid predendritic cells initiate psoriasis through interferon-α production
Nestle, F. O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O., Burg, G., Liu, Y.-J., & Gilliet, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050500 · Cited by 1,124
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Interferon‐α/β–mediated innate immune mechanisms in dermatomyositis
Greenberg, S. A., Pinkus, J. L., Pinkus, G. S., Burleson, T., Sanoudou, D., Tawil, R., Barohn, R. J., Saperstein, D. S., Briemberg, H. R., Ericsson, M., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20464 · Cited by 621
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Nickoloff, B. J., & Nestle, F. O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422147 · Cited by 544 · cited 1×
“Psoriasis is a chronic inflammatory skin disease in which T-cell–mediated cytokine production drives keratinocyte proliferation and angiogenesis.(24) Although TNFis a crucial cytokine in the inflammatory cascade leadTable 3.”
BackgroundBoyman, O., Hefti, H. P., Conrad, C., Nickoloff, B. J., Suter, M., & Nestle, F. O. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031482 · Cited by 522
Cross-regulation of TNF and IFN-α in autoimmune diseases
Palucka, A. K., Blanck, J.-P., Bennett, L., Pascual, V., & Banchereau, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408506102 · Cited by 516
A Randomized Trial of Etanercept as Monotherapy for Psoriasis
Gottlieb, A. B. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.12.1627 · Cited by 470
Gilliet, M., Conrad, C., Geiges, M., Cozzio, A., Thürlimann, W., Burg, G., Nestle, F. O., & Dummer, R. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.12.1490 · Cited by 408
De Bandt, M., Sibilia, J., Le Loët, X., Prouzeau, S., Fautrel, B., Marcelli, C., Boucquillard, E., Siame, J. L., Mariette, X., & Inflammation, T. C. R. E. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1715 · Cited by 401
Psoriasis induced by anti–tumor necrosis factor therapy: A paradoxical adverse reaction
Sfikakis, P. P., Iliopoulos, A., Elezoglou, A., Kittas, C., & Stratigos, A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21233 · Cited by 301
Vermi, W., Bonecchi, R., Facchetti, F., Bianchi, D., Sozzani, S., Festa, S., Berenzi, A., Cella, M., & Colonna, M. (2003) · The Journal of Pathology · doi:10.1002/path.1344 · Cited by 295
Flendrie, M., Vissers, W. H., Creemers, M. C., de Jong, E. M., van de Kerkhof, P. C., & van Riel, P. L. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1724 · Cited by 259
Wenzel, J., Wörenkämper, E., Freutel, S., Henze, S., Haller, O., Bieber, T., & Tüting, T. (2005) · The Journal of Pathology · doi:10.1002/path.1721 · Cited by 247
Baeten, D., Kruithof, E., Van den Bosch, F., Van den Bossche, N., Herssens, A., Mielants, H., De Keyser, F., & Veys, E. M. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.9.829 · Cited by 186
de Rycke, L., Baeten, D., Kruithof, E., Van den Bosch, F., Veys, E. M., & de Keyser, F. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21190 · Cited by 172
The central role of dendritic cells and interferon-α in SLE
Pascual, V., Banchereau, J., & Palucka, A. K. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200309000-00005 · Cited by 163
The human intracellular Mx‐homologous protein is specifically induced by type I interferons
Von Wussow, P., Jakschies, D., Hochkeppel, H., Fibich, C., Penner, L., & Deicher, H. (1990) · European Journal of Immunology · doi:10.1002/eji.1830200920 · Cited by 158
van der Fits, L., van der Wel, L. I., Laman, J. D., Prens, E. P., & Verschuren, M. C. M. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2003.22113.x · Cited by 132
Kary, S., Worm, M., Audring, H., Huscher, D., Renelt, M., Sörensen, H., Ständer, E., Maaß, U., Lee, H., Sterry, W., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.037424 · Cited by 125
Aeberli, D., Seitz, M., Jüni, P., & Villiger, P. M. (2004) · Rheumatology · doi:10.1093/rheumatology/keh437 · Cited by 90
Increased Sensitivity to Interferon-α in Psoriatic T Cells
Eriksen, K. W., Lovato, P., Skov, L., Krejsgaard, T., Kaltoft, K., Geisler, C., & Ødum, N. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23864.x · Cited by 85
Pustular psoriasis induced by infliximab.
Thurber, M., Feasel, A. M., Stroehlein, J., & Hymes, S. R. (2004) · PubMed · Cited by 78
Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases
Dereure, O., Guillot, B., Jørgensen, C., Cohen, J.-D., Combes, B., & Guilhou, J. J. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.06107.x · Cited by 71
Defining Upstream Elements of Psoriasis Pathogenesis: An Emerging Role For Interferon α
Nestle, F. O., & Gilliet, M. F. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23923.x · Cited by 60
Cited by
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Conrad, C., Di Domizio, J., Mylonas, A., Belkhodja, C., Demaria, O., Navarini, A. A., Lapointe, A.-K., French, L. E., Vernez, M., & Gilliet, M. (2018) · Nature Communications · doi:10.1038/s41467-017-02466-4 · Cited by 317
Ko, J. M., Gottlieb, A. B., & Kerbleski, J. F. (2009) · Journal of Dermatological Treatment · doi:10.1080/09546630802441234 · Cited by 313
Tillack, C., Ehmann, L. M., Friedrich, M., Laubender, R. P., Papay, P., Vogelsang, H., Stallhofer, J., Beigel, F., Bedynek, A., Wetzke, M., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-302853 · Cited by 302
Metadata
- Authors
- de Gannes, G. C., Ghoreishi, M., Pope, J., Russell, A., Bell, D., Adams, S., Shojania, K., Martinka, M., & Dutz, J. P.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2007-02-01
- Volume
- 143
- Issue
- 2
- Pages
- 223-31
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2149827116
- Cited by
- 325
- References
- 25
- FWCI
- 11.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.